Evidence map›Paper›PMID 40163066›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2025

Rapid ART, Rapid PrEP, and Status Neutral Implementation in Ryan White-Funded Clinics: Results From a Multisite Survey.

Joyce L Jones, Sheree Schwartz, Jessica E Kassanits, Maria Pyra, Russell A Brewer, Uyen Kao, Jill Blumenthal, Aadia I Rana, Tequetta Valeriano, Nanette D Benbow and 1 more

Abstract readMulticenter Study
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Joyce L JonesDivision of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD.
Sheree SchwartzDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Jessica E KassanitsInstitute for Sexual and Gender Minority Health and Wellbeing, Northwestern University Feinberg School of Medicine, Chicago, IL.
Maria PyraInstitute for Sexual and Gender Minority Health and Wellbeing, Northwestern University Feinberg School of Medicine, Chicago, IL.
Russell A BrewerDepartment of Medicine, University of Chicago, Chicago, IL.
Uyen KaoDepartment of Family Medicine, University of California, Los Angeles, Los Angeles, CA.
Jill BlumenthalDepartment of Medicine, University of California, San Diego, San Diego, CA.
Aadia I RanaDepartment of Medicine, University of Alabama-Birmingham Heersink School of Medicine, Birmingham, AL.
Tequetta ValerianoYale School of Nursing, Orange, CT; and.
Nanette D BenbowDepartment of Psychiatry and Behavioral Sciences, Northwestern University, Chicago, IL.
NISH 001 Study Team

Funding

Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul A. Goepfert · 1988 to 2026
$84.1M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN JANET LITTLE · 1994 to 2026
$78.4M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Anna Palmer Durbin · 2012 to 2026
$67.0M
Northwestern University Clinical and Translational Science Institute (NUCATS)UL1TR001422 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI D'AQUILA, RICHARD · 2015 to 2023
$56.8M
UCLA Rapid, Relevant, Rigorous Implementation Science HubP30MH058107 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Sung-Jae Lee · 1997 to 2026
$53.5M
Using Coincidence Analysis to Investigate Factors Affecting PrEP Initiation and Continuation in Southern ending the Epidemic CountiesP30MH062294 · NIMH · YALE UNIVERSITY · PI Trace S Kershaw · 2001 to 2026
$48.5M
Virology and Immunology Technology CoreP30AI117943 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Sahera Dirajlal-Fargo · 2015 to 2026
$38.4M
NCATS NIH HHS UL1 TR001422NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI036214NIAID NIH HHS P30 AI094189NIAID NIH HHS P30 AI117943NIMH NIH HHS P30 MH058107NIMH NIH HHS P30 MH062294
6 · The paper itself

Abstract

backgroundEnding the HIV Epidemic strategies include rapid ART Initiation (R-ART), rapid pre-exposure prophylaxis (R-PrEP), and status neutral approaches (status neutral), but implementation across heterogeneous settings in the United States is not well characterized.

settingRyan White (RW)-funded HIV treatment clinics located in select Ending the HIV Epidemic priority areas in the United States.

methodsClinics were sent a survey to assess experiences offering R-ART, R-PrEP, and status neutral (collectively called "rapid START"). Primary outcomes were rapid START adoption and characteristics of implementing vs. nonimplementing clinics. Secondary outcomes included perceptions, barriers, and facilitators of R-ART and R-PrEP.

resultsThe response rate was 48% (40 of 83). The 40 respondents represented 57 clinics who reported providing HIV-related services to more than 70,000 individuals annually. R-ART uptake was 85% (range 43%-100%), status neutral 65% (range 57%-75%), and R-PrEP 60% (range 0%-88%). No rural-identifying organizations reported offering R-ART or R-PrEP compared with 96% and 76% of urban-identifying organizations, respectively. Positive perceptions of acceptability, appropriateness, and feasibility for R-ART and R-PrEP were high among all levels of implementation and strongest among those offering R-ART and R-PrEP. The most frequent barriers to R-ART were provider- and clinic-level and for R-PrEP were system-level (lack of insurance coverage) followed by patient-, provider-, and clinic-level issues.

conclusionThis survey of diverse RW-funded clinics shows high uptake of R-ART and significant if less consistent uptake of R-PrEP and status neutral. Future research should focus on identifying broadly implementable strategies to expand adoption along with tailored approaches, especially in areas with lower health care access.

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisAmbulatory Care FacilitiesFemaleHumansMaleSurveys and QuestionnairesUnited StatesWhiteAnti-HIV Agents

Identifiers

PMID40163066
PMCPMC12742573

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.